CARROZZI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 16.477
AS - Asia 11.262
EU - Europa 8.600
SA - Sud America 2.205
Continente sconosciuto - Info sul continente non disponibili 901
AF - Africa 700
OC - Oceania 54
Totale 40.199
Nazione #
US - Stati Uniti d'America 15.967
IT - Italia 4.320
SG - Singapore 3.572
CN - Cina 2.397
HK - Hong Kong 2.170
BR - Brasile 1.781
VN - Vietnam 1.204
SE - Svezia 868
DE - Germania 606
BG - Bulgaria 589
FR - Francia 498
IN - India 380
GB - Regno Unito 372
RU - Federazione Russa 304
FI - Finlandia 290
TR - Turchia 282
CI - Costa d'Avorio 280
CA - Canada 274
JP - Giappone 263
KR - Corea 157
AT - Austria 139
BD - Bangladesh 139
AR - Argentina 134
NL - Olanda 134
IQ - Iraq 101
UA - Ucraina 91
ID - Indonesia 90
MX - Messico 90
PK - Pakistan 77
ZA - Sudafrica 77
CH - Svizzera 76
SN - Senegal 74
EC - Ecuador 63
PL - Polonia 62
CO - Colombia 60
SA - Arabia Saudita 56
VE - Venezuela 51
NG - Nigeria 50
MA - Marocco 49
AU - Australia 46
PH - Filippine 43
UZ - Uzbekistan 43
ES - Italia 41
PY - Paraguay 34
IE - Irlanda 32
AE - Emirati Arabi Uniti 30
TN - Tunisia 30
BE - Belgio 29
TT - Trinidad e Tobago 28
EG - Egitto 27
KE - Kenya 26
MY - Malesia 25
IR - Iran 24
CL - Cile 23
JM - Giamaica 23
JO - Giordania 22
TH - Thailandia 22
PE - Perù 20
UY - Uruguay 20
KZ - Kazakistan 19
CR - Costa Rica 18
PT - Portogallo 18
BJ - Benin 17
DZ - Algeria 17
NP - Nepal 17
GR - Grecia 16
RO - Romania 16
CZ - Repubblica Ceca 14
BO - Bolivia 13
DK - Danimarca 13
ET - Etiopia 13
IL - Israele 13
TW - Taiwan 13
LT - Lituania 12
HN - Honduras 11
HU - Ungheria 11
LB - Libano 11
OM - Oman 11
AL - Albania 10
BB - Barbados 10
PA - Panama 9
PS - Palestinian Territory 9
DO - Repubblica Dominicana 8
GT - Guatemala 8
AM - Armenia 7
AZ - Azerbaigian 7
BH - Bahrain 7
KH - Cambogia 7
NZ - Nuova Zelanda 7
SV - El Salvador 7
KW - Kuwait 6
LK - Sri Lanka 6
SY - Repubblica araba siriana 6
KG - Kirghizistan 5
LI - Liechtenstein 5
MD - Moldavia 5
NI - Nicaragua 5
NO - Norvegia 5
PR - Porto Rico 5
TZ - Tanzania 5
Totale 39.197
Città #
Ashburn 2.138
Hong Kong 2.133
Singapore 1.925
Dallas 1.180
San Jose 1.135
Santa Clara 1.035
Fairfield 744
Houston 708
Shanghai 705
Woodbridge 644
Chandler 601
Sofia 585
New York 539
Council Bluffs 459
Boardman 439
Ann Arbor 437
Beijing 430
Milan 422
Ho Chi Minh City 373
Seattle 353
Florence 349
Wilmington 341
Los Angeles 333
Princeton 332
Lawrence 292
Pisa 281
Abidjan 278
Lauterbourg 275
Cambridge 271
Hanoi 260
Tokyo 244
Rome 230
Hefei 223
Medford 211
Munich 201
Istanbul 173
Frankfurt am Main 152
São Paulo 142
Seoul 141
Buffalo 132
Redondo Beach 132
Helsinki 113
San Diego 113
Ottawa 112
Vienna 104
Chicago 93
London 89
Des Moines 87
Ogden 83
Jacksonville 81
Genoa 78
Nanjing 77
Dakar 74
Bremen 69
Turku 67
Naples 64
Lucca 57
Dong Ket 52
Belo Horizonte 51
Serra 51
Dearborn 50
Turin 50
Bologna 48
Warsaw 48
Da Nang 46
Nuremberg 46
Orem 45
Rio de Janeiro 44
Montreal 42
Palermo 42
Izmir 40
Pune 40
Washington 40
Phoenix 39
San Francisco 39
Baghdad 38
Atlanta 37
Denver 37
Johannesburg 37
Tashkent 37
Düsseldorf 36
Livorno 36
Brooklyn 35
Haiphong 35
Redwood City 35
Toronto 35
Bari 34
Catania 34
Lancaster 34
Amsterdam 33
Bern 33
Norwalk 32
Brasília 31
Mumbai 31
Dhaka 30
Dublin 29
Guangzhou 29
Chennai 28
Verona 28
Cascina 26
Totale 24.982
Nome #
Malattie respiratorie da droga - Ma.Re.D 1.525
null 346
Integrated environmental and clinical surveillance for the prevention of acute respiratory infections in closed settings and vulnerable communities: school, prison and nursing home (Stell-ARI Project) 269
A narrative review of epidemiology and prevention of lung cancer: sex/gender differences? 264
Idiopathic interstitial pneumonias: do HRCT criteria established by ATS/ERS/JRS/ALAT in 2011 predict disease progression and prognosis? 251
Usefulness of a compendium of respiratory standard questionnaires for adults (CORSQ) 249
Percorso di follow-up clinico, funzionale e radiologico dei pazienti dimessi con diagnosi di COVID-19 dall’Azienda Ospedaliero-Universitaria Pisana (AOUP) - Metodologia e arruolamento preliminare 240
C-C motive chemokine ligand 2 and thromboinflammation in COVID-19-associated pneumonia: A retrospective study 233
LHF Connect: A DIY telepresence robot against COVID-19 233
Reduction of risk of dying from tobacco-related diseases after quitting smoking in Italy 232
Epidemiologia ed effetti sulla salute del fumo di tabacco 231
Is There a Crucial Link Between Vitamin D Status and Inflammatory Response in Patients With COVID-19? 226
Investigating Promising Point-of-Care Diagnostics in Pleural Effusion: Assessment of Bedside Glucometer Accuracy for Pleural Fluid Glucose Versus Standard Laboratory and Blood Gas Analyser Methods 222
Standardized Clinical, Functional, and Radiological Pulmonary Follow-Up in Patients Discharged with Diagnosis of COVID-19 From an Italian Hospital - Preliminary Data 219
Integrated environmental and clinical surveillance of viral acute respiratory infections in close communities: opportunities and challenges 214
Appendix 3: Compendium of respiratory standard questionnaires for adults (CORSQ) 212
Thoracic Ultrasound for Pre-Procedural Dynamic Assessment of Non-Expandable Lung: A Non-Invasive, Real-Time and Multifaceted Diagnostic Tool 202
Patterns of Long COVID Symptoms: A Multi-Center Cross Sectional Study 199
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial 198
Impact of long-term exposure to cigarette smoking on skin microvascular function 195
Screen-detected multiple primary lung cancers in the ITALUNG trial 195
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study 191
Multimodal lung cancer screening using the ITALUNG Biomarker Panel and Low Dose Computed Tomography. Results of the ITALUNG biomarker study 187
Epidemiologia della broncopneumopatia cronico-ostruttiva: fattori di rischio ambientali ed occupazionali [Epidemiology of the chronic obstructive pulmonary disease: Environmental and occupational risk factors] 184
Venous Thromboembolism in Cancer: Frequently Asked Questions When Guidelines are Inconclusive 183
Basi fisiopatologiche, diagnosi e trattamento del tabagismo 183
Fattori individuali e ambientali di rischio respiratorio in soggetti vulnerabili che vivono in comunità chiuse (RSA e carcere): dati preliminari dello studio StellARI 181
Inclusion of peak expiratory flow for selection of the 'best' forced vital capacity manoeuvre 181
Idiopathic interstitial pneumonias: do HRCT criteria established by ATS/ERS/JRS/ALAT in 2011 predict disease progression and prognosis? 179
Prevalence of respiratory symptoms in an unpolluted area of northern Italy 178
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting 177
L'epidemiologia della broncopneumopatia cronica ostruttiva 176
Chromosome aberrations in humans in relation to site of residence. 175
Respiratory symptoms/diseases prevalence is still increasing: A 25-yr population study 174
Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) 168
Prescriptive adherence to GINA guidelines and asthma control: An Italian cross sectional study in general practice 168
Integrated environmental and clinical surveillance for the prevention of acute respiratory infections (ARIs) in indoor environments and vulnerable communities (Stell-ARI): Protocol 167
I centri antifumo in Italia e il progetto 6elle 167
Surgery for giant bullae in patients with and without COPD. 166
Definition, epidemiology and natural history of COPD 166
RItA: The Italian severe/uncontrolled asthma registry 166
Smooth reference equations for slow vital capacity and flow-volume curve indexes 163
Family history for chronic lung diseases and epidemiological determinants of COPD in three European countries 162
ARDS da prolasso mitralico acuto in assuntore di cocaina 162
L’attività dei Centri Antifumo italiani tra problematiche e aree da potenziare: i risultati di un’indagine svolta attraverso un questionario on-line 162
International association for the study of lung cancer computed tomography screening workshop 2011 report 160
A diagnostic strategy for pulmonary embolism based on standardised pretest probability and perfusion lung scanning: a management study 159
Serum antibodies to benzo(a)pyrene diol epoxide-DNA adducts in the general population: effects of air pollution, tobacco smoking, and family history of lung diseases 156
Reference equations for spirometry from a general population sample in central Italy 156
Life gain in Italian smokers who quit 154
Comparison of algorithms for determining the end-point of the forced vital capacity maneuver 152
A diagnostic strategy for pulmonary embolism based on standardized pretest probability and perfusion lung scanning ? A management study 151
Fumo di sigaretta in gravidanza: studio osservazionale prospettico in tre città della Toscana [Cigarette smoking in pregnancy: observational prospective study in three towns of Tuscany Region (Central Italy)] 151
Questionnaires, spirometry and PEF monitoring in epidemiological studies on elderly respiratory patients 151
Evaluation of severity of diffuse emphysema in patients with giant bullae before bullectomy 149
COPD management according to old and new GOLD guidelines: An observational study with Italian general practitioners 149
18-yr cumulative incidence of respiratory/allergic symptoms/diseases and risk factors in the Pisa epidemiological study 148
Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors 147
Respiratory symptoms/diseases, impaired lung function, and drug use in two Italian general population samples 146
Smoking Cessation in the ITALUNG Lung Cancer Screening: what does “teachable moment” mean? 146
Inferior vena cava filters: Concept review and summary of current guidelines 145
Pulmonary phenotypes and COVID-19 evolution patterns during the first year of the pandemic 145
Surgery for giant bullae in patients with and without COPD 145
Active and passive tobacco smoking 145
Molecular profile in body fluids in subjects enrolled in a randomised trial for lung cancer screening: Perspectives of integrated strategies for early diagnosis 145
Distribution of bronchial responsiveness in a general population: effect of sex, age, smoking, and level of pulmonary function 145
Quantitative CT Texture Analysis of COVID-19 Hospitalized Patients during 3–24-Month Follow-Up and Correlation with Functional Parameters 144
Radionuclide imaging in preoperative evaluation of bullous emphysema 144
Nicotine dependence and psychological distress: outcomes and clinical implications in smoking cessation 143
Depressive, anxious, withdrawal symptoms, and craving as possible predictors of abstinence maintenance in smokers attending a 12-week quitting program 141
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond 141
Influence of bulla volume on postbullectomy outcome 140
Percentiles of Inspiratory Capacity in Healthy Nonsmokers: A Pilot Study 139
Work-related asthma in a sample of subjects with established asthma 139
Multy-symptom asthma (msa) as indication of healthcare utilization burden (hub) in a cohort of Italian young asthmatic subjects 139
Retrospective Study on the Features and Outcomes of a Tuscany COVID-19 Hospitalized Patients Cohort: Preliminary Results 138
null 138
Urban residence is associated with bronchial hyper-responsiveness in Italian general population samples 138
Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19 138
Four-year results of low-dose CT screening and nodule management in the ITALUNG trial. 137
Early and late follow-up of pulmonary embolism 137
Long-term lung ultrasound follow-up in patients after COVID-19 pneumonia hospitalization: A prospective comparative study with chest computed tomography 135
Prospective study of a standardized questionnaire to improve clinical estimate of pulmonary embolism 135
Serum antibodies to benzo[a]pyrene diolepoxide-DNA adducts in the general population: effects of air pollution, tobacco smoking, and family history of lung diseases 135
Bronchitic symptoms in Italy and Sweden - Prevalence and risk factors 135
Respiratory symptoms/diseases and lifetime cumulative exposure to environmental tobacco smoke (ETS) in never smoker Italian women (SEASD Study) 134
Weight gain after smoking cessation 134
Prescriptive appropriateness using the new GOLD guidelines in the COMODHES study with Italian general practitioners 134
Five-year follow-up of pulmonary embolism under anticoaugulation: The PISA-PEET (Pulmonary Embolism Extension Therapy) study 132
Smoking reduction in smokers compliant to a smoking cessation trial with nicotine patch 132
Should perfusion scintigraphy be done to follow patients with acute PE? If so, when? 132
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 132
The Po River Delta epidemiological survey: Reference values of total serum IgE levels in a normal population sample of North Italy (8-78 yrs) 132
A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates 131
Short term longitudinal evaluation of smoking-related emphysema: analisys from Italung-CT Study 131
[Serum IgE, atopy, bronchial reactivity: details on female patients] 130
Changes in obesity status and lung function decline in a general population sample 130
Imaging medico-nucleare nella valutazione preoperatoria dell'enfisema nei pazienti con bolle giganti 129
Bullous emphysema: anuual decline of FEV1 after bullectomy 129
Integrating the care of the complex COPD patient 129
Totale 18.073
Categoria #
all - tutte 135.288
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 135.288


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.828 0 128 49 106 505 470 240 138 164 79 226 723
2022/20233.332 476 289 255 221 261 358 62 195 702 84 268 161
2023/20243.331 254 228 345 187 409 642 203 243 106 131 181 402
2024/202510.743 241 459 241 492 810 828 977 567 1.223 1.499 1.062 2.344
2025/202612.767 586 1.582 1.772 1.585 1.182 955 1.740 632 813 1.124 469 327
2026/20271.317 564 753 0 0 0 0 0 0 0 0 0 0
Totale 40.199